June 01, 2026 16:30 ET | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J., and TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 8,
Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS). June 01, 2026 16:05 ET | Source: Resmed, Inc. SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) — Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered
June 01, 2026 02:00 ET | Source: Curium PARIS, June 01, 2026 (GLOBE NEWSWIRE) — Curium, a global leader in nuclear medicine, today announced at the Choose France summit in Versailles, a major industrial investment program in France to the value of €32 million. This investment will strengthen its production capabilities for radiopharmaceuticals through the creation of
May 28, 2026 09:00 ET | Source: Royal Philips May 28, 2026 For the first time, Disney stories and characters will be integrated into Philips Ambient Experience for MRI at medical facilities around the world to help create calmer, more comfortable patient experiences Amsterdam, the Netherlands and Burbank, Calif. – Royal Philips (NYSE: PHG, AEX: PHIA) and The Walt Disney Company (NYSE:
May 27, 2026 08:00 ET | Source: Callio Therapeutics SEATTLE and SINGAPORE, May 27, 2026 (GLOBE NEWSWIRE) — Callio Therapeutics, a biotherapeutics company advancing dual-payload antibody-drug conjugates (ADCs) with a targeted, multi-mechanism approach to cancer treatment, today announced that it will present a trial-in-progress poster highlighting the Phase 1 trial design of CLIO-8221 at the 2026 American
May 26, 2026 21:18 ET | Source: Junshi Biosciences SHANGHAI, May 26, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (“NEOTORCH”, NCT04158440) of the
May 26, 2026 09:34 ET | Source: Cosmos Health Inc. CHICAGO, May 26, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced its financial guidance for the 2026–2029 period. Cosmos Health enters this guidance period following its strongest financial performance in Company history — full year 2025
AGC Biologics to provide process development and GMP manufacturing for a novel therapy, leveraging its global microbial network across Germany and Japan. May 25, 2026 20:00 ET | Source: AGC Biologics, Inc. HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 (GLOBE NEWSWIRE) — AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a
May 25, 2026 03:00 ET | Source: Boehringer Ingelheim Limited Boehringer Ingelheim today published new global survey findings revealing the often-overlooked aspects of veterinary care that are essential in protecting animals, people, and society. Drawing on responses from 1,046 qualifying veterinary professionals across 51 countries, the survey identified three of the most important yet underrecognized aspects of
May 22, 2026 08:15 ET | Source: Boehringer Ingelheim Limited Not intended for US and UK media Ingelheim, Germany – Boehringer Ingelheim’s JASCAYD® (nerandomilast) has been recommended for marketing authorization by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive
May 22, 2026 03:45 ET | Source: Boehringer Ingelheim Limited Not intended for UK and US media Ingelheim, Germany –Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) has been conditionally approved as monotherapy by China’s National Medical Products Administration (NMPA) as an initial treatment for adult patients with unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating
May 22, 2026 03:00 ET | Source: Global Liver Institute Geneva, Switzerland, May 22, 2026 (GLOBE NEWSWIRE) — Yesterday, Global Liver Institute (GLI), in collaboration with the Egyptian Ministry of Health and Population, convened a high-level policy event, on the sidelines of the Seventy-Ninth World Health Assembly (WHA79) to translate this global policy milestone into coordinated action. The event,
May 21, 2026 17:00 ET | Source: Boehringer Ingelheim Limited Not intended for US and UK media Ingelheim, Germany and Ridgefield, Conn., US –At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Boehringer Ingelheim will present new data from across its robust oncology clinical development program. Key data includes patient-reported outcomes with HERNEXEOS® (zongertinib tablets) as an initial orally administered treatment option for HER2 (ERBB2)-mutant advanced
May 21, 2026 12:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel and PARIS, May 21, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Medincell (Euronext: MEDCL), today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for
May 21, 2026 06:28 ET | Source: Junshi Biosciences SHANGHAI, May 21, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the new drug application (NDA) for toripalimab in combination with disitamab vedotin for
